A single predictor reflects most of events, but can be improved via other factors.16, 18, 30, 32 A previous study described NSCLC patients harboring STK11 mutation who had primary resistance to checkpoint inhibitors, although they had a high TMB.33 A similar phenomenon also exists in fist‐generation TKI therapy for those patients harboring concomitant mutations.34, 35 While our results showed that TMI could predict anlotinib response effectively, further analysis indicated that not all TMI full scored patients had a poor response to anlotinib. The gene discussed is STK11; the disease is non-small cell lung carcinoma.